Clinical Trial Update: Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial of CUDC-907 (fimepinostat) in children and young adults with relapsed or refractory solid tumors, CNS tumors, or lymphoma has completed, evaluat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Lymphoma
• Neuroblastoma
• Solid Tumor

Drugs mentioned

• CUDC-907 (fimepinostat)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Lymphoma, Neuroblastoma | Phase 1 | Status: COMPLETED